Ankyra Therapeutics

For nearly three decades, cancer researchers have known that a small protein called interleukin-12, or IL-12, is one of the most powerful anti-tumor signals the immune system can send. They also learned, painfully, that dosing it throughout the body could be dangerous. The drug worked too well, everywhere at once. So it sat on the shelf.

Ankyra Therapeutics, a roughly 25-person company headquartered at 83 Newbury Street in Boston, is built around a different question. Instead of asking how to make IL-12 safer chemically, its founders asked how to keep it in one place. Their answer - "anchored immunotherapy" - physically tethers the drug to aluminum hydroxide, the same well-understood material used as an adjuvant in common vaccines, so it stays lodged inside a tumor for weeks rather than washing into the bloodstream.

The result is a lead candidate, tolododekin alfa (also known as ANK-101), now moving through early-stage human trials. The company reports that across multiple difficult-to-treat solid tumor types, patients have so far seen no dose-limiting toxicities - the outcome that matters most when the whole premise is taming a drug once considered too toxic to use.

Ankyra's platform is not primarily a new molecule. It is a new address for old, powerful ones.

Immune-modulating drugs like cytokines can be extraordinarily effective at rallying the body's defenses against a tumor. Their weakness has always been reach: given systemically, they spread everywhere and trigger toxic, body-wide inflammation before they can do concentrated good. That trade-off - potency versus safety - has stalled a generation of promising therapies.

Ankyra's anchored immunotherapy platform attacks that trade-off directly. By complexing a therapeutic molecule with aluminum hydroxide (Alhydrogel) and injecting it into the tumor, the drug is retained locally. It stays concentrated where the cancer is, activating and recruiting effector immune cells over a sustained period, while systemic exposure - and the side effects that come with it - is sharply limited. The company likens the effect to an antibody-drug conjugate: potent activity focused on the tumor, with the rest of the body largely spared.

As a clinical-stage biotech, Ankyra has no product on the market yet. Its ultimate beneficiaries are cancer patients - people with advanced solid tumors who are treated through clinical trials at academic and cancer center sites. Its immediate stakeholders are the oncologists and clinical investigators running those studies, the pharmaceutical partners it collaborates with, and the investors funding the work.

Ankyra sits within a fast-moving corner of immuno-oncology focused on localized and intratumoral therapy. It shares that space with companies exploring masked or tumor-activated cytokines and other IL-12 approaches - names such as Werewolf Therapeutics, Xilio Therapeutics and Synthekine - and, more broadly, competes for relevance against the systemic checkpoint inhibitors and cytokine therapies of large immuno-oncology players. Its differentiator is mechanical rather than purely molecular: where much of the field engineers the drug itself, Ankyra engineers where the drug stays.

Ankyra is a venture-backed research-and-development company. Value is created by advancing proprietary drug candidates through clinical trials toward regulatory approval - with likely routes to revenue through partnerships, licensing, out-licensing of the platform, or acquisition. It carries an estimated annual revenue in the low single-digit millions, consistent with a pre-commercial biotech funded by equity rounds rather than product sales.

Its expertise is unusually concentrated. The founding science comes straight from MIT bioengineering, and the clinical program is led by a veteran of tumor immunotherapy. That combination - materials science and drug delivery on one side, deep immuno-oncology clinical experience on the other - is the company's real moat.

Howard L. Kaufman, M.D. serves as President and Chief Executive Officer. A leading authority on tumor immunotherapy and oncolytic viruses - and previously chief medical officer at Replimune - Kaufman joined Ankyra as CMO in 2021 and now leads the company's clinical strategy. Co-founder Darrell Irvine has also launched Elicio Therapeutics and Strand Therapeutics; co-founder Dane Wittrup co-founded Adimab and Cullinan.